Tag Archives: CRBP

Hot Warren Buffett Stocks To Own For 2021

PeepCoin (CURRENCY:PCN) traded 70.2% higher against the dollar during the 24-hour period ending at 13:00 PM ET on August 14th. During the last week, PeepCoin has traded 1.4% higher against the dollar. One PeepCoin coin can currently be bought for $0.0000 or 0.00000000 BTC on popular cryptocurrency exchanges including Trade Satoshi, CoinExchange, C-Patex and Cryptopia. PeepCoin has a total market cap of $497,805.00 and $5,648.00 worth of PeepCoin was traded on exchanges in the last 24 hours.

Here’s how other cryptocurrencies have performed during the last 24 hours:

Get PeepCoin alerts:

Aeternity (AE) traded 17.7% lower against the dollar and now trades at $0.89 or 0.00014709 BTC. Hshare (HSR) traded 18.2% lower against the dollar and now trades at $2.50 or 0.00041370 BTC. ARBITRAGE (ARB) traded down 8.9% against the dollar and now trades at $2.05 or 0.00033863 BTC. NevaCoin (NEVA) traded up 0.2% against the dollar and now trades at $0.0293 or 0.00000485 BTC. CryptoWorldX Token (CWXT) traded flat against the dollar and now trades at $0.0004 or 0.00000006 BTC. Axiom (AXIOM) traded down 3.9% against the dollar and now trades at $0.0070 or 0.00000115 BTC.

PeepCoin Profile

Hot Warren Buffett Stocks To Own For 2021: Intercept Pharmaceuticals, Inc.(ICPT)

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid, a bile acid analog, that completed Phase III clinical trials for the treatment of primary biliary cholangitis and Phase II clinical trials for the treatment of nonalcoholic fatty liver disease; and is in Phase III clinical trials for the treatment of nonalcoholic steatohepatitis, Phase II clinical trials for the treatments of primary sclerosing cholangitis, and Phase II clinical trial for the treatment of biliary atresia. The company is also developing INT-767, an orally administered dual FXR and TGR5 agonist, which is in Phase I clinical trial for the treatment of fibrosis; and INT-777, an orally administered TGR5 agonist that is in preclinical stage for the treatment of type 2 diabetes. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

Advisors’ Opinion:

  • [By George Budwell]

    Intercept Pharmaceuticals (NASDAQ:ICPT), a mid-cap drugmaker focusing on diseases of the liver, saw its shares lose 14.5% of their value last month,according to data fromS&P Global Market Intelligence. Prior to last month’s pullback, Intercept’s shares were up by almost 80% over the last 12 months.

  • [By Jon C. Ogg]

    Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) was last seen trading after the company’s financial reporting. While numbers are always important to see, a more subjective issue is a positive review from Wall Street.

  • [By Motley Fool Transcribing]

    Intercept Pharmaceuticals (NASDAQ:ICPT) Q4 2018 Earnings Conference CallFeb. 28, 2019 8:30 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Hot Warren Buffett Stocks To Own For 2021: ImmuCell Corporation(ICCC)

ImmuCell Corporation was founded in 1982 and completed an initial public offering of common stock in 1987. After achieving approval from the U.S. Department of Agriculture (USDA) to sell First Defense庐 in 1991, we focused most of our efforts during the 1990’s developing human product applications of the underlying milk protein purification technology. Beginning in 1999, we re-focused our business strategy on First Defense庐 and other products for the dairy and beef industries. During the first quarter of 2016, we sold 1.1 million shares of common stock in an underwritten public offering registered with the Securities and Exchange Commission (SEC), raising net proceeds of $5.3 million. Our purpose is to create scientifically-proven and practical products that improve animal health and productivity in the dairy and beef industries.   Advisors’ Opinion:

  • [By Max Byerly]

    ImmuCell Co. (NASDAQ:ICCC) Director David Scott Tomsche purchased 3,000 shares of the firm’s stock in a transaction dated Thursday, August 16th. The stock was purchased at an average cost of $6.67 per share, with a total value of $20,010.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

  • [By Stephan Byrd]

    ImmuCell (NASDAQ:ICCC) released its quarterly earnings results on Monday. The biotechnology company reported ($0.04) earnings per share for the quarter, Bloomberg Earnings reports. ImmuCell had a negative net margin of 1.61% and a negative return on equity of 0.79%.

Hot Warren Buffett Stocks To Own For 2021: Brightcove Inc.(BCOV)

Brightcove Inc., or Brightcove, is a leading global provider of cloud-based services for video. Brightcove was incorporated in Delaware in August 2004 and our headquarters are in Boston, Massachusetts. Our suite of products and services reduces the cost and complexity associated with publishing, distributing, measuring and monetizing video across devices.
Brightcove Video Cloud, or Video Cloud, our flagship product released in 2006, is the world’s leading online video platform. Video Cloud enables our customers to publish and distribute video to Internet-connected devices quickly, easily and in a cost-effective and high-quality manner. Brightcove Zencoder, or Zencoder, is a cloud-based video encoding service. Brightcove Once, or Once, is an innovative, cloud-based ad insertion and video stitching service that addresses the limitations of traditional online video ad insertion technology.   Advisors’ Opinion:

  • [By Logan Wallace]

    Brightcove (NASDAQ:BCOV) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Brightcove (BCOV)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Motley Fool Transcribers]

    Brightcove Inc (NASDAQ:BCOV)Q42018 Earnings Conference CallFeb. 13, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Brightcove (BCOV)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Warren Buffett Stocks To Own For 2021: Information Services Group Inc.(III)

Information Services Group, Inc. operates as a fact-based sourcing advisory company principally in the Americas, Europe, and the Asia Pacific. It provides strategic consulting, benchmarking and analytics, managed services, and research services with a focus on information technology, business process transformation, and enterprise resource planning. The company serves financial services, telecom, healthcare and pharmaceuticals, manufacturing, transportation and travel, and energy and utilities industries; and state and local governments and airport and transit authorities. Information Services Group, Inc. was founded in 2006 and is based in Stamford, Connecticut.

Advisors’ Opinion:

  • [By Logan Wallace]

    Canaccord Genuity upgraded shares of Imperial Metals (TSE:III) from a hold rating to a buy rating in a research note published on Monday. They currently have C$4.00 price objective on the stock, up from their prior price objective of C$1.65.

  • [By Logan Wallace]

    Martingale Asset Management L P bought a new position in Information Services Group, Inc. Common Stock (NASDAQ:III) during the second quarter, Holdings Channel reports. The fund bought 110,416 shares of the business services provider’s stock, valued at approximately $453,000.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Information Services Group, Inc. Common Stock (III)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Warren Buffett Stocks To Own For 2021: Corbus Pharmaceuticals Holdings, Inc.(CRBP)

Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. Its lead product candidate, Resunab, is a novel oral anti-inflammatory drug that is expected to commence Phase IIa clinical trials for the treatment of cystic fibrosis and diffuse systemic sclerosis diseases. The company is based in Norwood, Massachusetts.

Advisors’ Opinion:

  • [By Motley Fool Transcription]

    Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Q4 2018 Earnings Conference CallMarch 12, 2019, 8:30 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Keith Speights]

    Biotech

    GW Pharmaceuticals (NASDAQ:GWPH) $3.7 billion

    Cara Therapeutics (NASDAQ: CARA) $697 million

    Insys Therapeutics (NASDAQ: INSY) $473 million

    22nd Century Group (NYSEMKT: XXII) $313 million

    Corbus Pharmaceuticals (NASDAQ: CRBP) $271 million

    Ancillary provider

  • [By Todd Campbell]

    ETFMG Alternative Harvest ETF

    Company Percent of Holdings
    Canopy Growth Corp. (NYSE:CGC) 9.85%
    Cronos Group Inc. (NASDAQ: CRON) 9.48%
    Aurora Cannabis Inc. (NASDAQOTH:ACBFF) 9.3%
    Tilray, Inc. (NASDAQ:TLRY) 9.2%
    GW Pharmaceuticals PLC (NASDAQ:GWPH) 6.78%
    CannTrust Holdings (NASDAQOTH: CNTTF) 4.63%
    Hydropothecary Corp. (NASDAQOTH: HYYDF) 4.56%
    Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) 3.46%
    Green Organic Dutchman Holding (NASDAQOTH: TGODF)

    3.36%

  • [By Keith Speights]

    Three of the biggest winners this week were Viking Therapeutics (NASDAQ:VKTX), Acadia Pharmaceuticals (NASDAQ:ACAD), and Corbus Pharmaceuticals (NASDAQ:CRBP). What drove these biotech stocks higher — and are they buys now?

Hot Warren Buffett Stocks To Own For 2021: Hudson Global, Inc.(HSON)

Hudson Global, Inc. provides professional-level recruitment and related talent solutions for small to large-sized corporations and government agencies worldwide. The company offers permanent recruitment services; and temporary contracting services, such as project management, interim management, and professional contract staffing services. It also offers recruitment process outsourcing services, such as complete recruitment outsourcing, project-based outsourcing, contingent workforce solutions, and recruitment consulting services to multinational companies; and talent management solutions, including talent assessment, interview training, executive coaching, employee development, and outplacement. The company was formerly known as Hudson Highland Group, Inc. and changed its name to Hudson Global, Inc. in April 2012. Hudson Global, Inc. was founded in 2003 and is based in New York, New York.

Advisors’ Opinion:

  • [By Shane Hupp]

    JBF Capital Inc. purchased a new position in Hudson Global Inc (NASDAQ:HSON) in the second quarter, Holdings Channel reports. The fund purchased 157,917 shares of the business services provider’s stock, valued at approximately $256,000.

Best Clean Energy Stocks To Watch Right Now

Related KOL Coal Companies Lobby For Clean Energy Subsidies Silver Shines Among 2016's Best ETFs

The VanEck Vectors Coal ETF (NYSE: KOL) was one of last year's best-performing non-leveraged exchange-traded funds for a simple reason: Of the two nominees for the U.S. presidency, one was vocal in her disdain for the coal industry while one vowed to restore the industry's lost jobs.

President Donald Trump, obviously, was the candidate that promised to restore coal country's lost glory and KOL responded. The ETF is doing so again this year with a year-to-date gain of almost 18 percent. That means KOL has nearly doubled in value over the past year. Still, there are ample indications that Trump's promises to coal miners will be hard to keep.

Best Clean Energy Stocks To Watch Right Now: Novo Nordisk A/S(NVO)

Advisors’ Opinion:

  • [By James E. Brumley]

    When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.

    In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.

    While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.

    As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’

  • [By Logan Wallace]

    Eagle Global Advisors LLC decreased its position in Novo Nordisk (NYSE:NVO) by 10.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 130,420 shares of the company’s stock after selling 15,550 shares during the period. Eagle Global Advisors LLC’s holdings in Novo Nordisk were worth $6,423,000 as of its most recent SEC filing.

  • [By Paul Ausick]

    Novo Nordisk A/S (NYSE: NVO) dropped about 1.5% on Friday to post a new 52-week low of $32.35 after closing at $32.84 on Thursday. The stock’s 52-week high is $59.00. Volume of about 3.4 million was close to the daily average of around 3.9 million shares. The drug maker had no specific news.

  • [By Brian Orelli]

    Novo Nordisk (NYSE:NVO) continues its trend ofrelatively strong growth of its newer diabetes medications being offset by slower growth of older insulin drugs in the first quarter. Currency changes also negatively affected Novo’s revenue line, but that’s out of the company’s control.

  • [By Brian Orelli]

    Global Blood Therapeutics (NASDAQ:GBT) is up 20% at 3:42 p.m. EST after Reuters reported that Novo Nordisk (NYSE:NVO) has approached the biotech about a potential acquisition.

Best Clean Energy Stocks To Watch Right Now: Adaptimmune Therapeutics plc(ADAP)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Adaptimmune Therapeutics (NASDAQ:ADAP) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.20, Bloomberg Earnings reports. Adaptimmune Therapeutics had a negative return on equity of 32.26% and a negative net margin of 185.39%. During the same quarter in the prior year, the business earned ($3.00) EPS.

  • [By Jon C. Ogg]

    Adaptimmune Therapeutics PLC (NASDAQ: ADAP) was started with a Market Perform at Wells Fargo.

    Aqua America Inc. (NYSE: WTR) was raised to Overweight from Equal Weight and the price target was raised to $36 from $33 (versus a $31.19 close) at Barclays.

Best Clean Energy Stocks To Watch Right Now: SITO Mobile, Ltd.(SITO)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Birchview Capital LP lifted its position in shares of SITO Mobile (NASDAQ:SITO) by 16.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 140,000 shares of the Wireless communications provider’s stock after acquiring an additional 20,000 shares during the period. SITO Mobile accounts for 0.4% of Birchview Capital LP’s portfolio, making the stock its 25th biggest holding. Birchview Capital LP’s holdings in SITO Mobile were worth $563,000 at the end of the most recent reporting period.

Best Clean Energy Stocks To Watch Right Now: Corbus Pharmaceuticals Holdings, Inc.(CRBP)

Advisors’ Opinion:

  • [By Sean Williams]

    This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.

    GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%

    As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!

  • [By Keith Speights]

    Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus’ share price has soared 550%.

best stock for investment

When John Milligan speaks, people listen — especially if they’re Gilead Sciences (NASDAQ:GILD) shareholders.

The big biotech’s CEO and its CFO Robin Washington sat down to field questions at the RBC Capital Markets 2017 Healthcare Conference in New York City on Wednesday. Milligan spoke directly to some of the most pressing concerns for Gilead shareholders. Here are three things he said that you’ll definitely want to know.

Image source: Getty Images.

1. We don’t know when the HCV business will bottom out.

The biggest worry on the minds of Gilead shareholders relates to the plunging sales for the biotech’s hepatitis C virus (HCV) franchise. John Milligan couldn’t — and didn’t — give any reason to think that there was a light at the end of the tunnel.

Milligan stated that Gilead doesn’t know if the HCV business will stabilize yet, and added that the company “might not know until it happens.” He said that his team initially thought that things might have stabilized last year, but “the dynamic didn’t play out as expected.”

best stock for investment: Iridium Communications Inc(IRDM)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap satellite stock Iridium Communications (NASDAQ: IRDM) reportedQ2 2017 earnings before the market opened on Thursday with results beating expectations. Total revenueincreased 2% to $111.6 million which consisted of $86.6 million of service revenue and $25.0 million of revenue related to equipment sales and engineering and support projects.Service revenue, which represents primarily recurring revenue from Iridium’s growing subscriber base, grew 4% and was 78% of total revenue. The Company ended the quarter with 913,000 total billable subscribers, which compares to 823,000 for the year-ago period and is up from 869,000 for the quarter ended March 31, 2017.Total billable subscribers grew 11% year-over-year, driven by growth in M2M and government customers. Net income was $24.8 million versus $26.9 million for the second quarter of 2016. The CEO commented:

  • [By Jim Robertson]

    Trump’s proposal to spin off air traffic control from the Federal Aviation Administration (FAA) bodes well for small cap satellite stock Iridium Communications (NASDAQ: IRDM), but theres a bigger opportunity for the Company in theInternet of Things (IoT) space. Technology company Harris Corporation (NYSE: HRS) is already a leading candidate to supply the FAA with real-time aircraft tracking data in partnership with Iridium Communications with the latter having a joint venture that has partnered with air traffic control authorities in Canada, Italy, Ireland and Denmark to provide air traffic surveillance (in cooperation with Harris).

best stock for investment: Microbot Medical Inc. (MBOT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares shot up 51 percent to $7.76 after reporting a significant technology patent allowance in the U.S. The patent allowance covers a device for the prevention of shunt stenosis.

  • [By Lisa Levin]

    Shares of Microbot Medical Inc (NASDAQ: MBOT) got a boost, shooting up 15 percent to $8.77 after the company reported a 700,000 share direct offering for $3.5 million.

  • [By Lisa Levin]

    Microbot Medical Inc (NASDAQ: MBOT) shares dropped 34 percent to $2.50. Microbot Medical reported a $10 million registered direct offering

    Shares of NewLink Genetics Corp (NASDAQ: NLNK) were down 12 percent to $11.13 after the company reported that indoximod + PROVENGE resulted in statistically significant improvement in rPFS for patients with mCRPC in Phase 2 trial.

best stock for investment: E*TRADE Financial Corporation(ETFC)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Meanwhile, E*Trade (NASDAQ:ETFC) decided to split the difference. Effective March 13, E*Trade’s commission structure will get split in two. Base rate customers will see their commissions fall from $9.99 to $6.95 per trade, matching TD Ameritrade. However, E*Trade created a new structure for active traders, defined as those who execute 30 or more trades every three months. For those customers, E*Trade will have $4.95 per trade commissions, and options charges will fall by a third, to $0.50 per contract. CEO Karl Roessner said that although “an exceptional customer experience is far more important to traders and investors than price, with our new commission structure, we are able to reward our most active equity and derivative traders and investors.”

  • [By Jon C. Ogg]

    E*Trade Financial Corp. (NASDAQ: ETFC) was up another 1.6% at $32.97. Ithas a total market cap of $9 billion, and over the past five trading days the stock has gained 17%. Shares of Morgan Stanley (NYSE: MS) were last seen at $39.09, up 17% in the past fivetrading days. The market cap is$74.7 billion.

  • [By Chris Neiger]

    This article will walk your through all the steps for setting up an individual E*TRADE (NASDAQ:ETFC) brokerage account, which should only take about five to 10 minutes to complete. If you want to compare offers from other brokers, or view their features, check out ourbroker comparison page.

  • [By David Zeiler]

    In just three years, Robinhood’s customer base has surpassed that of entrenched online brokerage E*Trade Financial Corp. (Nasdaq: ETFC), which spent 35 years accumulating 3.6 million customers.

best stock for investment: Xenon Pharmaceuticals Inc.(XENE)

Advisors’ Opinion:

  • [By Jim Robertson]

    Yesterday, our Under the Radar Moversnewsletter suggested going long on small cap biopharmaceutical stock Xenon Pharmaceuticals Inc (NASDAQ: XENE):

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 51 percent to $4.80 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 53 percent to $4.68 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

best stock for investment: DBV Technologies S.A.(DBVT)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Losers
    DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.
    Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market.
    Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring.
    Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation.
    Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04.
    Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring.
    Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday.
    Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550
    OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share.
    Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
    Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting.
    Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo

  • [By Monica Gerson]

    DBV Technologies SA ADR (NASDAQ: DBVT) is expected to post a quarterly loss at $0.60 per share.

    Northern Technologies International Corp (NASDAQ: NTIC) is projected to post its quarterly earnings.

  • [By Paul Ausick]

    DBV Technologies SA (NASDAQ: DBVT) dropped about 53.5% Monday to post a new 52-week low of $22.33 after closing at $48.07 on Friday. The stock’s 52-week high is $50.57. Volume of around 12 million was about 60 times the daily average. The French drug maker’s peanut allergy treatment failed a phase 3 study.

best stock for investment: Corbus Pharmaceuticals Holdings, Inc.(CRBP)

Advisors’ Opinion:

  • [By Sean Williams]

    This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.

    GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%

    As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!

  • [By Keith Speights]

    Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus’ share price has soared 550%.